The power of RESILIA tissue*†
For patients referred for surgical valve replacement, there are now three options: mechanical valves, conventional tissue valves, or RESILIA tissue valves. When it comes to quality of life, a higher proportion of patients with mechanical valves vs. tissue valves have reported dissatisfaction or uncertainty about their valve choice.1
RESILIA tissue gives surgeons the freedom to offer a resilient tissue alternative that brings the quality-of-life benefits of tissue valves to patients. That’s why Edwards Lifesciences is advancing the future of cardiac surgery with a growing portfolio of valves designed with RESILIA tissue.
RESILIA tissue offers freedom
The power of Edwards Lifesciences’ heart valves with RESILIA tissue is freedom. For surgeons, it is the freedom to focus on what matters most: patient wellbeing. RESILIA tissue offers the possibility of avoiding costly surgical re-intervention later in life when risks may be higher.
RESILIA tissue is the result of several generations of tissue valve innovation that started with the Carpentier-Edwards PERIMOUNT valve in 1981. Our continued advancement of tissue technology has led to a unique understanding of associated challenges and the best ways to address them.
A key challenge when it comes to pericardial tissue is structural valve deterioration (SVD), much of which is due to calcium buildup. RESILIA tissue is transformed to resist calcification differently.
The RESILIA tissue portfolio represents the best creative scientific minds coming together to address unmet needs and satisfy patient demands for better surgical options. Currently, RESILIA tissue technology is featured on our portfolio of surgical tissue products: INSPIRIS RESILIA aortic valve, KONECT RESILIA aortic valved conduit, and MITRIS RESILIA mitral valve.
Edwards Lifesciences maintains its strong commitment to leadership in surgical heart valve development. That's why RESILIA tissue is the backbone of our future surgical heart valve development.
Learn more about how your patients can benefit from life to the power of RESILIA.
*RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg 2015;149:340–5.
†No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.
Subscribe
Sign up for future updates related to Edwards Lifesciences news!